Aligos Therapeutics Inc Stock

$8.04

0.25% yesterday

Nasdaq, Sep 27, 10:00 pm CET

ISIN

US01626L1052

Symbol

ALGS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Aligos Therapeutics Inc Stock price

$8.04

-366.96 97.86% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

+0.02 0.25%

ISIN

US01626L1052

Symbol

ALGS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$25.63m
Enterprise Value	$-59.14m
EV/FCF (TTM) EV/FCF	0.69
EV/Sales (TTM) EV/Sales	-7.42
P/S ratio (TTM) P/S ratio	3.22
P/B ratio (TTM) P/B ratio	0.38
Revenue growth (TTM) Revenue growth	-53.82%
Revenue (TTM) Revenue	$7.97m
EBIT (operating result TTM) EBIT	$-93.53m
Free Cash Flow (TTM) Free Cash Flow	$-85.33m
Cash position	$94.61m
P/E forward	negative
P/S forward	9.86
EV/Sales forward	negative
Short interest	0.81%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Aligos Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Aligos Therapeutics Inc forecast:

3x Buy

100%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Aligos Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Aligos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	7.97 7.97	54% 54% 100%
- Direct Costs	2.74 2.74	20% 20% 34%
Gross Profit	5.23 5.23	62% 62% 66%
- Selling and Administrative Expenses	20 20	12% 12% 256%
- Research and Development Expense	76 76	5% 5% 948%
EBITDA	-91 -91	12% 12% -1,139%
- Depreciation and Amortization	2.74 2.74	20% 20% 34%
EBIT (Operating Income) EBIT	-94 -94	10% 10% -1,174%
Net Profit	-76 -76	8% 8% -950%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aligos Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

9 days ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-...

Neutral

GlobeNewsWire

●

9 days ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone...

Neutral

GlobeNewsWire

●

15 days ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to pur...

More Aligos Therapeutics Inc News

Company Profile

Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Lawrence Blatt
Employees	66
Founded	2018
Website	www.aligos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now